CTH Cotec Holdings Corp

Cynapsus Therapeutics Inc. (TSX VENTURE:CTH), a specialty pharmaceutical company
developing the only known orally administered (sublingual) formulation of
apomorphine, the only drug approved to treat the immobility ("off") symptoms of
Parkinson's disease, has completed a white paper providing background clinical
information on apomorphine. The paper identifies the potential benefits of
APL-130277, the company's proprietary, patented, sublingual thin-film strip
system, specifically its ability to deliver apomorphine to patients in a more
convenient and more well-tolerated manner.


Anthony Giovinazzo, President and Chief Executive Officer of Cynapsus, stated:
"We have been receiving requests for a more comprehensive, clinically based
summary of apomorphine, covering its benefits, drawbacks and known side effects,
as well as a summary of our development delivery candidate APL-130277-all in a
single document. Accordingly, we have composed this background paper, which is
now available on our website. It offers useful information to anyone who is
interested in these topics."


The white paper is titled "Apomorphine for Off Periods in Parkinson's Disease:
Clinical Use and Potential of a Developmental Sublingual Formulation,
APL-130277". It summarizes the medical literature on the freezing or "off"
episodes experienced by 25 percent to 50 percent of Parkinson's patients. It
goes on to identify how apomorphine works as an acute intermittent rescue
treatment. Further, it summarizes some of the most pertinent data from a recent
survey of 500 neurologists worldwide regarding the number of patients who will
potentially experience these "off" episodes. It then identifies past efforts to
find new delivery methods and the benefits of the new APL-130277 sublingual
approach. The paper reviews clinical data generated to date and further data
expected through the remainder of 2013. It also includes predictions by the 500
neurologists regarding the potential use of the new delivery method by
Parkinson's patients who experience the "off" episodes.


A copy of the full paper is available at the Cynapsus website, www.cynapsus.ca.

About Cynapsus Therapeutics

Cynapsus is a specialty pharmaceutical company developing the only known orally
administered (i.e. sublingual) delivery of the only approved drug (apomorphine)
to be used as a rescue therapy for "off" motor symptoms of Parkinson's disease.
Apomorphine is currently primarily delivered as an inconvenient and painful
subcutaneous injection. Over one million people in the U.S. and an estimated 5
million people globally suffer from Parkinson's disease. Parkinson's disease is
a chronic and progressive neurodegenerative disease that impacts motor activity,
and its prevalence is increasing with the aging of the population. Based on a
recent study and the results of the Company's Global 500 Neurologists Survey, it
is estimated that between 25 percent and 50 percent of patients experience "off"
episodes in which they have impaired movement or speaking capabilities. Current
medications only control the disease's symptoms, and most drugs become less
effective over time as the disease progresses. Cynapsus' drug candidate,
APL-130277, is an easy-to-administer, fast-acting reformulation of apomorphine,
which is approved in an injection formulation to rescue patients from "off"
episodes. 


Cynapsus is focused on maximizing the value of APL-130277 by completing pivotal
studies in advance of a New Drug Application expected to be submitted in 2015.
Cynapsus anticipates a trade sale or out-licensing to an appropriate global
pharmaceutical partner before such an application is submitted.


More information about Cynapsus (TSX VENTURE:CTH) is available at
www.cynapsus.ca and at the System for Electronic Document Analysis and Retrieval
(SEDAR) at www.sedar.com. 


Forward Looking Statements

This announcement contains "forward-looking statements" within the meaning of
applicable Canadian securities legislation. Generally, these forward-looking
statements can be identified by the use of forward-looking terminology such as
"plans", "expects" or "does not expect", "is expected", "budget", "scheduled",
"estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or
"believes" or variations of such words and phrases or state that certain
actions, events or results "may", "could", "would", "might" or "will be taken",
"occur" or "be achieved". Forward-looking statements are subject to known and
unknown risks, uncertainties and other factors that may cause the actual
results, level of activity, performance or achievements of Cynapsus to be
materially different from those expressed or implied by such forward-looking
statements, including but not limited to those risks and uncertainties relating
to Cynapsus' business disclosed under the heading "Risk Factors" in its Annual
Information Form filed on November 1, 2012 and its other filings with the
various Canadian securities regulators which are available online at
www.sedar.com. Although Cynapsus has attempted to identify important factors
that could cause actual results to differ materially from those contained in
forward-looking statements, there may be other factors that cause results not to
be as anticipated, estimated or intended. There can be no assurance that such
statements will prove to be accurate, as actual results and future events could
differ materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward-looking statements. Cynapsus
does not undertake to update any forward-looking statements, except in
accordance with applicable securities laws.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Cynapsus Therapeutics
Anthony Giovinazzo
President and CEO
(416) 703-2449 x225
ajg@cynapsus.ca


Cynapsus Therapeutics
Andrew Williams
COO & CFO
(416) 703-2449 x253
awilliams@cynapsus.ca
www.cynapsus.ca

Cotec (TSXV:CTH)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024

Cotec (TSXV:CTH)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024